475 articles with MorphoSys AG
Interim data from all patients enrolled in ongoing L-MIND trial of MOR208 in combination with lenalidomide in relapsed/refractory DLBCL confirm activity suggested by earlier data cuts
MorphoSys Provides Updates on L-MIND and B-MIND Clinical Trials of MOR208 in Relapsed/Refractory DLBCL
MorphoSys AG provided updates on L-MIND and B-MIND, its two ongoing clinical trials of the investigational Fc- enhanced anti-CD19 antibody MOR208 in patients with relapsed or refractory diffuse large B cell lymphoma, who are not eligible for high-dose chemotherapy and autologous stem cell transplantation.
MorphoSys AG will publish its Annual Financial Results 2018 on March 13, 2019 at 10:00pm CET.
MorphoSys Announces that its Licensee Janssen Has Received U.S. FDA Approval for Tremfya(R) One-Press Patient-Controlled Injector for Adults with Moderate-to-Severe Plaque Psoriasis
MorphoSys AG announced that its licensee Janssen Research & Development, LLC, has reported that the U.S. Food and Drug Administration has approved Tremfya One-Press, a single-dose, patient-controlled injector for adults with moderate-to-severe plaque psoriasis.
FINCH 2 Phase 3 trial with filgotinib in rheumatoid arthritis (RA) met all primary and secondary endpoints, with consistent tolerability
MorphoSys AG will present at the following conference.
Simon Moroney, CEO and co-founder of MorphoSys AG informed the Company’s Supervisory Board that he has decided not to renew his contract as a member of the company’s Management Board.
Planegg/Munich, Germany, February 19, 2019 Simon Moroney, CEO and co-founder of MorphoSys AG, informed the Company’s Supervisory Board that he has decided not to renew his contract as a member of the company’s Management Board.
MorphoSys Announces Appointment of David Trexler as President and Member of the Board of Directors of MorphoSys US Inc.
MorphoSys AG announced the appointment of David R. Trexler as President and member of the Board of Directors of MorphoSys US Inc., effective February 6, 2019.
MorphoSys AG announced today that in its lawsuit against Janssen Biotech and Genmab A/S, the parties have settled the dispute.
Ad hoc: MorphoSys Announces That Its Patents Were Ruled Invalid in Patent Lawsuit Against Janssen and Genmab
MorphoSys AG announces that it was informed that in its lawsuit against Janssen Biotech and Genmab A/S, the United States (U.S.) District Court of Delaware has ruled in a Court Order on January 25, 2019, that the asserted claims of three MorphoSys patents with U.S. Patent Numbers 8,263,746, 9,200,061 and 9,758,590 are invalid.
MorphoSys Announces that its Licensee Janssen has Expanded Clinical Development of Guselkumab (Tremfya(R)) into Ulcerative Colitis
MorphoSys AG announced that its licensee Janssen Research & Development, LLC (Janssen), has further expanded the clinical development of guselkumab (Tremfya(R)) into ulcerative colitis (UC).
MorphoSys's Licensee Janssen Announces Data from the Phase 3 Head-to-Head Study ECLIPSE Demonstrating Superiority of Tremfya(R) vs. Cosentyx(R) as Measured by PASI 90 at Week 48 in the Treatment of Plaque Psoriasis
MorphoSys AG reported today that its licensee Janssen has announced that results from the ECLIPSE study demonstrated that Tremfya(R) (guselkumab) was superior to Cosentyx(R) (secukinumab) in treating adults with moderate to severe plaque psoriasis for the primary endpoint of a PASI 90 response at week 48.
Ad hoc: MorphoSys Announces that According to a Presentation Title at an Upcoming Conference, Guselkumab Demonstrates Superior Long-Term Responses to Secukinumab at Week 48 in the Treatment of Moderate to Severe Psoriasis
MorphoSys AG announced today that according to the title of a presentation to be held next Wednesday afternoon CET (December 12, 2018) at the upcoming Inflammatory Skin Disease Summit (ISDS) conference in Vienna, Austria, guselkumab [Tremfya(R)] demonstrates superior long-term responses to secukinumab [Cosentyx(R)] at Week 48 in the treatment of moderate to severe psoriasis, as results from the ECLIPSE trial.
MorphoSys Presents Updated Data from L-MIND Study of MOR208 in combination with Lenalidomide in r/r DLBCL at ASH 2018
MorphoSys AG today presented data from the ongoing single-arm phase 2 clinical trial known as L-MIND in an oral presentation at the 60th American Society of Hematology (ASH) Annual Meeting 2018 in San Diego, USA.
MorphoSys Announces Approval of Tremfya(R) (Guselkumab) in Japan for the Treatment of Patients with Palmoplantar Pustulosis
MorphoSys AG announced today that its licensee's affiliate, Janssen Pharmaceutical K.K. (Janssen) reported that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Tremfya(R) (guselkumab) for the treatment of patients with palmoplantar pustulosis who are not responding or are refractory to existing treatments.
MorphoSys Announces Its Licensee Janssen Initiated a Phase 2 Study (NOVA) to Evaluate Guselkumab in Hidradenitis Suppurativa
MorphoSys AG announced today that its licensee Janssen Research & Development, LLC (Janssen) initiated a phase 2 clinical study of guselkumab in patients with moderate to severe hidradenitis suppurativa (HS), a chronic skin disease also known as acne inversa.
MorphoSys and I-Mab Sign Strategic Partnering Agreement for MorphoSys's Novel Immuno-Oncology Agent MOR210
MorphoSys AG and I-Mab Biopharma jointly announced today that they have entered into an exclusive strategic collaboration and regional licensing agreement for MOR210. MOR210 is MorphoSys's proprietary, preclinical-stage antibody directed against C5aR
This year has been a strong one for biotech initial public offerings (IPO). According to the Wall Street Journal, as of mid-October, 55 biotech companies had raised $5.75 billion.
Advancing proprietary pipeline; solid progress in partnered programs